Business
NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
GENinCode Plc announced a collaboration with the North Central London Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch a Risk of Ovarian Cancer Algorithm (ROCA) surveillance test service. UCLH is the first UK hospital trust to offer this service as part of its Familial Cancer Clinic, in line with new NICE guidance for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations. Women with BRCA1 or BRCA2 gene alterations have a 44% and 17% lifetime risk of ovarian cancer, respectively, up to age 80. Studies show the ROCA Test reduces late-stage ovarian cancer detections (stage III and IV) by 44%. Disclaimer*
About this update from Genincode Plc
[{"type":"text","content":"\n\n \n \n25 September 2025\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nNHS (UCLH) launches Risk of Ovarian Cancer (ROCA) surveillance service for women at high risk\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (\"CVD\") and risk of ovarian cancer announces its collaboration with the North Central London (NCL) Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH), which becomes the first hospital trust in the UK to provide the Risk of Ovarian Cancer Algorithm (ROCA) surveillance test service as part of its Familial Cancer Clinic. The service, in line with new NICE guidance1, is for women who have a high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations, who wish to defer preventative surgery.\n \nWomen who carry a cancer-causing variant in the BRCA1 or BRCA2 gene have a 44% and 17% respectively in their lifetime risk of ovarian cancer (\"OC\") up to the age of 80 years. Around one in every 400 people carries a cancer-causing variant in the BRCA1 or BRCA2 gene. They are advised to undergo surgical removal of their fallopian tubes and ovaries to prevent OC. This remains the safest option for this group of patients. NICE guidance also recommends that surveillance should be offered to women who choose to defer surgery to be able to have children and/or avoid early menopause. UCLH is the first trust in the country to offer this surveillance on the NHS, outside of a trial setting. \n \nThe ROCA Test's proprietary algorithm calculates a woman's individual risk based on several clinical factors. These include cumulative Cancer Antigen 125 (CA 125) blood test results, age, menopausal status and the presence of a BRCA1 or BRCA2 gene alteration. Having the ROCA blood test every four months improves the chances of early detection of ovarian cancer (pre-stages III and IV). Early detection improves treatment outcomes.\n \nThree key prospective studies have been conducted using the ROCA Test with women at high-risk of OC. The first UK study UKFOCSS was led by University College London (UCL). Based on the reduction in late-stage ovarian cancer seen in this trial, a 'real world' NHS implementation study, ALDO was initiated to assess the feasibility of ROCA surveil...